OBJECTIVES: To evaluate in daily clinical practice possible changes in perceived quality of life (QoL) in patients treated with solifenacin and also to investigate whether the treatment had an impact on the use of incontinence pads. METHODS: This non-interventional study consisted of one visit at the study centres per patient and two follow-up questionnaires (13-item QoL and 6-item bother scale, OAB-q SF) after 3 months and 6 months, answered by the patients at home. RESULTS: A total of 232 patients were included in the study at 35 centers in Sweden. Sixty patients participated at baseline only. The age of patients ranged from 25 to 87 years (mean 64 years). One hundred and sixty-seven patients (97.1%) were women and 5 patients (2.9%) were men. Almost all of the participating investigators were specialists in gynecology, which explains the large proportion of women among the patients. Solifenacin significantly improved self-perceived health-related quality of life, as measured by the 13-item QoL scale of the OAB-q SF, at 3 months vs. baseline (p <.0001) and at 6 months vs. baseline (p <.0001) and also when 6 months and 3 months data were compared (p=0.007), in anti-muscarinic naive OAB patients. Solifenacin significantly improved self-perceived health-related quality of life, as measured by the 6-item bother scale of the OAB-q SF, at 3 months vs. baseline (p <.0001) and at 6 months vs. baseline (p <.0001). The mean use of pads significantly decreased from 19 to 12 pads per week. Solifenacin significantly decreased the use of pads at 3 months vs. baseline (p <.0001) and at 6 months vs. baseline (p <.0001). CONCLUSIONS: Solifenacin significantly improved self-perceived health-related quality of life, as measured by  both the 13-item QoL scale and the 6-item bother scale of the OAB-q SF. Solifenacin significantly decreased the use of pads per week.